Mouse Anti-APP Recombinant Antibody (clone PFA1) (CAT#: PABW-009)

Recombinant Mouse Antibody (PFA1) is capable of binding to APP. This anti-Aβ monoclonal antibody has been shown to reduce amyloid plaques in vitro and in animal studies.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 SPR reveals Aβ peptide binding to PFA1 via the EFRHD epitope.

Figure 1 SPR reveals Aβ peptide binding to PFA1 via the EFRHD epitope.

(a) Kinetic analysis of Aβ(1–40) (WT) monomer at 0, 1.23, 3.70, 11.1, 33.3, 100, and 300 nM, binding to PFA1 Fab immobilized at densities of 2,720 response units (RU) (shown) and 1,280 RU (data not shown). Duplicate binding responses for each monomer concentration are overlaid with the global fit of a simple 1:1 interaction model (smooth lines), which yielded k a = (1.431 ± 0.003) × 104 M−1 s−1, k d = (5.58 ± 0.01) × 10−4 s−1, and K d = 39.0 ± 0.1 nM. (b) WT and Ala-substituted mutants of Aβ(1–40) monomers were sequentially flowed over PFA1 IgG captured on anti-IgG flow cell surfaces (SPR). Significant RU peaks show good peptide binding, whereas the absence of a peak shows no binding. Results from PFA2 were essentially identical. The D7A mutation limits but does not completely eliminate binding. The numbering scheme is Aβ(1–40)-specific.

Gardberg, A. S., Dice, L. T., Ou, S., Rich, R. L., Helmbrecht, E., Ko, J., ... & Dealwis, C. (2007). Molecular basis for passive immunotherapy of Alzheimer's disease. Proceedings of the National Academy of Sciences, 104(40), 15659-15664.

Figure 2 Plasma Aβ is decreased in 22 month old PFA1 treated female mice and increased in 22 month old PFA1 treated male mice.

Figure 2 Plasma Aβ is decreased in 22 month old PFA1 treated female mice and increased in 22 month old PFA1 treated male mice.

A. Aβ1-40 levels were measured from plasma collected from vehicle and PFA1 treated female mice before and after 4 weeks of treatment. There was no significant change in plasma Aβ1-40 levels following treatment in vehicle treated animals. There was a significant 44% decrease (p < 0.01) in plasma Aβ1-40 levels following PFA1 treatment. B. Aβ1-42 levels were measured from plasma collected from vehicle and PFA1 treated female mice before and after treatment. There were no significant changes to Aβ1-42 in either the vehicle or PFA1 group following treatment. C. Aβ1-40 levels were measured from plasma collected from vehicle and PFA1 treated male mice before and after 4 weeks of treatment. There was no significant change in plasma Aβ1-40 levels following treatment in vehicle treated male mice. There was a significant 128% increase (p < 0.05) in Aβ1-40 levels following treatment in the PFA1 treated male mice. D. Aβ1-42 levels were measured from plasma collected from male mice before and after vehicle or PFA1 treatment. There were no significant changes to Aβ1-42 levels following treatment in either vehicle or PFA1 group.

Minami, S. S., Sidahmed, E., Aid, S., Shimoji, M., Niikura, T., Mocchetti, I., ... & Bosetti, F. (2010). Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease. Journal of neuroinflammation, 7(1), 57.

Figure 3 The protofibril monoclonal antibody PFA1 recognizes multiple Aβ species.

Figure 3 The protofibril monoclonal antibody PFA1 recognizes multiple Aβ species.

5 μL of serum (S) and 10 μg of soluble protein extract from brains (B) of 22 month old AD 3 × tg mice were immunoblotted for Aβ with antibody PFA1 (left) or 6E10 (right). 1 μM synthetic Aβ40 and Aβ42 (right lanes) were loaded for comparison. Membranes were cut at 15 kDa to subject the lower panels to a longer exposure for detection purposes. PFA1 detected the 56 kDa oligomeric form of Aβ from serum with high affinity, similar to 6E10.

Minami, S. S., Sidahmed, E., Aid, S., Shimoji, M., Niikura, T., Mocchetti, I., ... & Bosetti, F. (2010). Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease. Journal of neuroinflammation, 7(1), 57.


Specifications

  • Immunogen
  • Human amyloid beta (A4) precursor protein
  • Host Species
  • Mouse
  • Derivation
  • Mouse
  • Type
  • Mouse IgG2a
  • Specificity
  • APP
  • Species Reactivity
  • Human
  • Clone
  • PFA1
  • Applications
  • ELISA

Product Property

  • Purity
  • >95% as determined by analysis by SDS-PAGE
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • APP; amyloid beta (A4) precursor protein; AAA; AD1; PN2; ABPP; APPI; CVAP; ABETA; PN-II; CTFgamma; amyloid beta A4 protein; preA4; protease nexin-II; peptidase nexin-II; beta-amyloid peptide; beta-amyloid peptide(1-40); beta-amyloid peptide(1-42); alzheimer disease amyloid protein; cerebral vascular amyloid peptide

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone PFA1"

See other products for "APP"

Single-domain Antibody

CAT Product Name Application Type
NABG-016 Recombinant Anti-Human APP VHH Single Domain Antibody CA, IP, IF, FuncS Llama VHH
TAB-0019CL-VHH Camelid Anti-APP Recombinant Antibody (TAB-0019CL-VHH) IHC, WB Camelid VHH
TAB-0020CL-VHH Anti-Human APP VHH Single Domain Antibody (MPL D7) ELISA, IHC Single domain antibody
TAB-0021CL-VHH Anti-Human APP VHH Single Domain Antibody (MPL C2) ELISA, In vivo, FuncS Single domain antibody
TAB-0022CL-VHH Anti-Human APP VHH Single Domain Antibody (MPL H3) ELISA, In vivo, FuncS Single domain antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0685MZ Chicken Anti-APP Polyclonal IgY IHC Chicken antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-225 Afuco™ Anti-APP ADCC Recombinant Antibody (Bapineuzumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC ADCC enhanced antibody
AFC-TAB-228 Afuco™ Anti-APP ADCC Recombinant Antibody (Solanezumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC ADCC enhanced antibody
AFC-TAB-229 Afuco™ Anti-APP ADCC Recombinant Antibody (Gantenerumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC, IP ADCC enhanced antibody
AFC-TAB-227 Afuco™ Anti-APP ADCC Recombinant Antibody (Ponezumab), ADCC Enhanced ELISA, IP, FC, FuncS, Neut ADCC enhanced antibody
AFC-TAB-226 Afuco™ Anti-APP ADCC Recombinant Antibody (Crenezumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABW-009. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare